Comparison of Initial Intraocular Pressure Response With Topical β-Adrenergic Antagonists and Prostaglandin Analogues in African American and White Individuals in the Ocular Hypertension Treatment Study

Abstract

To compare the intraocular pressure (IOP) responses of self-identified African American and white participants in the Ocular Hypertension Treatment Study to therapeutic trials of topical, nonselective ␤-adrenergic antagonists or prostaglandin analogues.Methods: Multivariate models that adjusted for baseline IOP and corneal thickness were used to estimate IOP response by race. Participants included 536 who were prescribed topical ␤-adrenergic antagonists and 191 who were prescribed prostaglandin analogues, 25% of whom were African American.Main Outcome Measure: Intraocular pressure response in the ipsilateral eye after 4 to 6 weeks of a therapeutic trial.Results: Intraocular pressure response to nonselective ␤-adrenergic antagonists did not differ between African American and white participants. Intraocular pressure response to prostaglandin analogues was slightly greater in African American participants, but this difference was not statistically significant. With both classes of medication, greater IOP reduction was associated with higher baseline IOP and thinner central corneal measurement. Conclusions:We found no statistically significant differences in IOP response to topical, nonselective ␤-adrenergic antagonists or prostaglandin analogues between self-identified African American and white individuals. Application to Clinical Practice: Studies of IOP response to medication should statistically adjust for baseline IOP and central corneal thickness. Clinicians should consider factors other than ethnicity when choosing an ocular hypotensive medication for a patient.

A Novel 8-mm Schlemm's Canal Scaffold Reduces Outflow Resistance in a Human Anterior Segment Perfusion Model

“…This pattern is similar to the outcome of other studies of the effects of IOPlowering interventions, in which greater IOP lowering correlated with higher baseline IOP. [23][24][25] Outflow resistance has been reported to be higher at higher levels of IOP. [26][27][28] One possible cause for increased resistance is collapse of the SC at higher pressures.…”

The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma

“…One major risk factor for glaucoma is the raised IOP. However, other mechanisms must be involved in the pathology of glaucoma because glaucoma can develop in the absence of elevated IOP and, in the clinic, different individuals respond differently to the elevated pressure [60]. In some populations, patients may have high eye pressure for many years but this never leads to glaucoma.…”

Current primary open-angle glaucoma treatments and future directions

“…This implies that some patients cannot meet the American Academy of Ophthalmology initial IOP reduction target of 25% of the baseline IOP on latanoprost alone. Latanoprost, as well as beta blockers, are thought to be potent drugs,27,30 and one study found no significant differences between beta blockers and PGAs 31. Consequently, all could be used as first-line monotherapy agents, including other PGAs like bimatoprost or travoprost 27…”